Lercanidipine and labedipinedilol-A play anti-inflammatory role through inhibition of lipopolysaccharide/interferon-γ-induced HMGB1 release and MMP-2, 9 activities in vascular smooth muscle cells

CNU IR > Pharmacy and Science > 2015 > Item 310902800/31156

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/31156

Title:	Lercanidipine and labedipinedilol-A play anti-inflammatory role through inhibition of lipopolysaccharide/interferon-γ-induced HMGB1 release and MMP-2, 9 activities in vascular smooth muscle cells
Authors:	Shu-Fen Liou(劉淑芬) Ling-Cheng Kao(高翎程)
Contributors:	Department and Graduate Institute of Pharmacology, College of Medicine, Kaohsiung Medical University
Date:	2015-05-05
Issue Date:	2018-03-27 10:24:14 (UTC+8)
Abstract:	Inflammation is an important molecular basis of atherosclerosis. Recent studies have shown that dihydropyridine calcium channel blockers (CCBs) can exert potent anti-inflammatory effects in models of vascular dysfunction. The purpose of the present study was to evaluate anti-inflammatory effects and mechanisms of lercanidipine and labedipinedilol-A, new generation dihydropyridine CCBs, in rat vascular smooth muscle cells (VSMCs) exposed to lipopolysaccharide (LPS) and interferon-γ (IFN-γ). MTT, Griess reagent, RT-PCR, ELISA, gelatin zymography, immunocytochemistry and Western blotting were employed. We found that lercanidipine and labedipinedilol-A attenuated production of NO, ROS, TNF-α and IL- from LPS/IFN-γ-stimulated VSMCs. In addition, they both diminished the LPS/IFN-γ-induced expression of iNOS protein and mRNA, with attenuation of HMGB1 cytosolic translocation and subsequent extracellular release. Furthermore, they down-regulated MMP-2/MMP-9 activities, while expression of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), an inhibitor of MMP-9, was up-regulated. Finally, we found that lercanidipine and labedipinedilol-A inhibited the nuclear translocation of NF-κB and suppressed the phosphorylation of JNK, p38 MAPK and Akt. In conclusion, lercanidipine and labedipinedilol-A can exert their anti-inflammatory effects through suppression of NO, ROS, TNF-α and IL- through down-regulation of iNOS, MMP-2/MMP-9, and HMGB1, with inhibition of signaling transduction of MAPKs, Akt/IkB-α and NF-κB pathways. These findings implicate a valuable role of new generation dihydropyridine CCBs lercanidipine and labedipinedilol-A inthe treatment of inflammatory vascular diseases.
Relation:	2015 第九屆嘉南藥理大學藥理學院師生研究成果發表會，起迄日：2015/05/05-2015/05/08，地點：嘉南藥理大學國際會議中心一樓
Appears in Collections:	[Pharmacy and Science] 2015

Files in This Item:

File	Description	Size	Format
B03.pdf		595Kb	Adobe PDF	237	View/Open

Loading...